非小细胞肺癌寡转移的立体定向放射治疗研究

doi:10.11904/j.issn.1002-3070.2018.02.013

Abstract

Abstract: Non-small cell lung cancer(NSCLC)is the most common type of distant metastasis in all types of lung cancer except for SCLC,including brain,bone,liver and adrenal gland.Of the patients with distant metastases in NSCLC,not all cases are multiple and extensive,with nearly 7% of patients presenting with isolated extrapulmonary metastases.This particular form of advanced tumor metastasis is called NSCLC oligometastatic.Treatment of oligometastatic is mainly local treatment,which includes stereotactic radiotherapy(STR),surgical resection and radiofrequency ablation.The aim of this article is to discuss the effect of SRT on the micrometastasis of common distant metastatic organs in NSCLC.

Key words: Non-small cell lung cancer, Oligodendrocyte metastasis, Stereotactic radiotherapy

CLC Number:

R730.55

DU Yesheng, HU Songliu, XU Xiangying. Study of oligodendrocyte metastasis in non-small cell lung cancer by stereotactic radiotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 154-158.

References

1 Luketich JD,Martini N,Ginsberg RJ,et al.Successful treatment of solitary extraeranial metastases from non-small cell lung cancer[J].Ann Thorac Surg,1995,60(6):1609-1611.
2 Weichselbaum RR,Hellman S.Oligometastases revisited[J].Nat Rev Clin Oncol,2011,8(6):378-382.
3 Yamashita H,Niibe Y,Yamamato T,et al.Lung stereotactic radiotherapy for oligometastases:comparison of oligo-recurrence and sync-oligometastases[J].Jpn J Clinl Oncol,2016,46(7):687-691.
4 Salah S,Tanvetyanon T,Abbasi S.Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases systematic review analysis of reported cases[J].Lung Cancer,2012,75(1):9-14.
5 Juan O,Popat S.Ablative therapy for oligometastatic non-small cell lung cancer[J].Clin Lung Cancer,2017,18(6):595-606.
6 Kennedy TAC,Corkum MT,Louie AV.Stereotactic radiotherapy in oligometastatic cancer[J].Chin Clin Oncol,2017,6(Suppl 2):16.
7 Inoue T,Katoh N.Aoyama H,et al.Clinical outcomes of stereotacticbrain and body radiotherapy or patients with oligometastatic lesions[J].Jpn J Clin Oncol,2010,48(8):788-794.
8 Bai H,Xu J,Yang H,et al.Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy[J].Onco Targets Ther,2016,11(9):4207-4013.
9 Miyazawa K,Shikama N,Okazaki S,et al.Predicting prognosis of short survival time after palliative whole-brain radiotherapy[J].J Radiat Res,2017,24(10):1-7.
10 Pessina F,Navarria P,Cozzi LT,et al.Outcome appraisal of patients with limited brain metastases(BMs)from non small cell lung cancer(NSCLC)treated with different local therapeutic strategies:a single institute evaluation[J].Br J Radiol[J].2017,90(1072):1259-1273.
11 Soliman H,Das S,Larson DA,et al.Stereotactic radiosurgery(SRS)in the modern management of patients with brain metastases[J].Oncotarget,2016,7(11):12318-12330.
12 Zabel SM,Thilmnn C,Zuna I,et al.Treatment of brain metastases in patients with non-small cell lung cancer by stereotactic linac-based radiosurgery:prognostic factors[J].Lung Cancer,2002,37(1):87-94.
13 Schuttrumpf LH,Niyazi M,Nachbichler SB,et al.Prognostic factors for survival and radioation necorsis after stereotactic radiosurgery alone or in combination with whole brain radioation therapy for 1-3 cerebral metastases[J].Radiat Oncol,2014,9(2):1748-1755.
14 Kaul D,Angelidis A,Budach V,et al.Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer[J].Radiat Oncol,2015,10(2):1186-1199.
15 Nibe Y,Nishimura T,Inoue T,et al.Oligo-recurrent predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy:a multi-institutional study of 61 subjects[J].BMC Cancer,2016,16(1):659-667.
16 Miller DA,Krasna MJ.Local therapy indications in the management of patients with oligometastatic non-small cell lung cancer[J].Surg Oncol Clin N Am,2016,25(3):611-620.
17 Minniti G,Salvati M,Muni R,et al.Stereotacticradio surgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer[J].A nticancer Res,2010,30(7):3055-3061.
18 Balducci M,Autorino R,Chiesa S,et al.Radiosurgery plus whole brain radiotherapy in brain oligometastases:a long term analysis[J].Anticancer Res,2015,35(5):3055-3059.
19 Kougioumtzopoulou A,Zygogianni A,Liakouli Z,et al.The role of radiotherapy in bone metastases:A critical review of current literature[J].Eur J Cancer Care(Engl),2017,5(1):181-205.
20 Tseng CL,Eppinga W,Charest-Morin R,et al.Spinestereotactic body radiotherapy:indications,outcomes,and points of caution[J].Global Spine J,2017,7(2):179-197.
21 Bhattacharya IS,Hoskin PJ.Stereotactic body radiotherapy for spinal and bone metastases[J].Clin Oncol,2015,27(5):298-306.
22 Napieralska A,Miszczyk L,Stapor-Fudzinska M.Cyber knife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases[J].Neoplasma,2016,63(2):304-312.
23 Adebahr S,Collette S,Shash E,et al.Lung Tech,an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours:a clinical perspective[J].Br J Radiol,2015,88(3):383-387.
24 Wild AT,Yamada Y.Stereotactic body radiation therapy focus on colorectal cancer[J].Visc Med,2017,33(1):54-61.
25 McGinn CJ,Ten Haken RK,Endminger WD,et al.Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model[J].J Clin Oncol,1998,16(6):2246-2252.
26 Lanciano R,Lamond J,Yang J,et al.Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors[J].Int J Radiat Oncol Bio Phys,2012,10(2):23-36.
27 Goodman BD,Mannina EM,Althouse SK,et al.Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases[J].Pract Radiat Oncol,2016,6(2):86-95.
28 Rule W,Timmerman R,Tong L,et al.Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases[J].Ann Surg Oncol,2011,18(4):1081-1087.
29 Rusthoven KE,Kavanagh BD,Cardenes H.et al.Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases[J].Clin Oncol,2009,27(10):1572-1578.
30 Berkovic P,Gulyban A,Nguyen PV,et al.Stereotactic robotic body radiotherapy for patients with unresectable hepatic oligorecurrence[J].Clin Colorectal Cancer,2017,21(3):1533-1550.
31 Ippolito E,D'Angelillo RM,Fiore M,et al.SBRT:A viable option for treating adrenal gland metastases[J].Rep Pract Oncol Radiother,2015,20(6):484-490.
32 Milano MT,Katz AW,Zhang H,et al.Oligometastases treated with stereotactic body radiotherapy:a long term follow-up of prospective study[J].Int J Radiat Oncol Biol Phys,2012,83(3):878-886.
33 Casamassima F,Livi L,Masciullo S,et al.Stereotactic radiotherapy for adrenal gland metastases:university of florence experience[J].Int J Radiat Oncolbiol Phys,2012,82(2):919-923.
34 Rudra S,Malik R,Ranck MC,et al.Stereotactic body radiation therapy for curative treatment of adrenal metastases[J].Technol Cancer Res Treat,2013,12(3):217-224.

[1]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[2]	CAI Jing, HOU Yue. The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 415-419.
[3]	CUI Xiaoyan,TU Qing,GAN Jianhui. Comparison between nalbuphine and oxycodone applied for patient controlled analgesia on postoperative immunological factor levels in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 309-314.
[4]	LEI Junhua, XU Guanhua, ZENG Jiangzheng, HUANG Fen, HE Zhihui, LU Yanda. Research on JAK3/STAT3 mechanism of non-small cell lung cancer NCI-H1975 cells treated with cryptotanshinone combined with cisplatin [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 198-202.
[5]	ZHAI Keke, GAO Yuanyuan, FENG Xiao, XU Jingwen, GONG Yufang, MENG Qingwei. Analysis of first-line NSCLC chemotherapy in the phase Ⅳ patients with distant metastasis and first diagnosis after postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 107-111.
[6]	SUN Mingliang, XU Jianyu, XU Xiangying. Stereotactic radiotherapy for early stage of non - small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 53-56.
[7]	DAI Xin, ZHANG Daxin. Current status of anti-angiogenesis therapy for non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 472-476.
[8]	HU Haifeng,FENG Xiemin,QIAO Jian,DUAN Wei,LIU Ningning,SUN Xiaodong. The expression and clinical significance of miR-345 in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 117-122.
[9]	ZHANG Rui,WANG Zhiyu,WANG Shuai,ZHAO Hui. Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diagnosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 527-522.
[10]	REN Fenghai,WANG Dandan,WANG Junfeng,XU Hai,XU Shidong. Clinical comparative study between Uniportal and single port video-assisted thoracoscopic surgery for ⅠA stage non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 327-331.
[11]	YE Leiguang, YAN An, LIU Baogang. Relationship between Aurora-A mediated drug resistance and prognosis of patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 97-102.
[12]	CHEN Minghui, CHEN Xijie, WANG Yan. Research progress of CD44v6 in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 172-175.
[13]	CHENG Long, ZHOU Jianguo, ZHOU Hang. Maintenance therapy with pemetrexed for advanced non-small cell lung cancer:A Meta-analysis of RCTs [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 28-35.
[14]	WANG Lei,CHEN Gongyan. Research progress of Hedgehog-Gli signaling pathway in lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 178-182.
[15]	ZHOU Daming,LU Qingfeng,CHEN Guangyu. ERCC1 expression and prognosis in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 524-529.

Study of oligodendrocyte metastasis in non-small cell lung cancer by stereotactic radiotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments